European Journal of Rheumatology
Short Communication

Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic


Department of Medicine, Johns Hopkins University School of Medicine


Department of Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria

Eur J Rheumatol 2020; 7: Supplement S121-128
DOI: 10.5152/eurjrheum.2020.2067
Read: 2227 Downloads: 1051 Published: 23 July 2020

Since the first description of infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China in December 2019, it has evolved into a pandemic and emerged as an unprecedented worldwide crisis overwhelming healthcare systems globally. Analysis of the available literature to date suggests that, in addition to older age, patients with underlying co-morbidities including hypertension, diabetes, heart disease are at higher risk for severe disease with increased mortality. Practitioners around the world also have become increasingly concerned that immunosuppressed patients including those with autoimmune diseases may be at increased risk for developing Coronavirus Disease 2019 (COVID-19) with serious complications. Very little is known about how anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis modifies the susceptibility, clinical presentation and disease course of COVID-19. In this review, we discuss the mechanism of action and challenges of the current therapeutic armamentarium of ANCA-associated vasculitis and outline approaches to management of ANCA-associated vasculitis during the COVID-19 pandemic.

Cite this article as: Gapud EJ, Kronbichler A, Gauckler P, Geetha D. Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic. Eur J Rheumatol 2020; 7(Suppl 2): S121-8.

EISSN 2148-4279